NaniRx is a drug development company affiliated with Columbia University Medical Center with a primary focus on Precision Immune-Stimulants (PINS™) for the treatment of breast cancer and on Precision Tolerogens (PT™), immune-suppressors for the treatment of autoimmune disorders. NaniRx has been able to uncover the mechanism of action of a small biological contained within the AIDS virus which is responsible for controlling the immune system. The precise manipulation of the distinct activities contained within this biological is the key to our ground-breaking program. This revolutionary drug development platform combines a specific delivery of activity from outside a cell to inside its nucleus; once inside, it is able to dictate either immune stimulation or suppression.